Replies to post #223233 on Biotech Values

[DewDiligence]

RVNC—…add to that JPM19 breakfast meeting followed by showcasing ‘ground breaking’ data, you have perfect storm for big pharma to take notice.

RVNC’s Special Investor Breakfast at JPM, which was hosted by Cowen, was plainly for the purpose of lining up institutional investors—not for discussing potential partnerships with other drug/biotech companies:

What a great meeting! Thank you Dr Dover and Dr Fabi for your insights and thank you to @cowenresearch for hosting such an amazing event with us! $rvnc#jpm2019 #jpm19 #biotechweek19 #aestheticmedicine#medaesthetics #dermatology #innovation #clinicaltrials #neuromodulation pic.twitter.com/dmMlXvnzY9

— Revance (@revance) January 9, 2019

[dewophile]

There is no clock for a partnership. These things are impossible to predict.

Intermune is a good example. They had positive data in early 2014, raised money a couple months later. they got bought out a few months after that for double the offering price before even FDA approval. Why sell shares a few short months before a buyout? Simple - interested parties can turn up unexpectedly and quickly sometimes, or adjust the terms to where management is ready to pull the trigger.